LRMR Stock Forecast & Price Target

Larimar Therapeutics is supported by compelling nomlabofusp data showing durable frataxin restoration and aligned clinical improvement, with 82% of patients reaching carrier-like skin frataxin levels at six months and 100% at one year and 18 months. The company’s regulatory position also looks favorable, as the rolling BLA is on track for 2H26, the FDA feedback was described as constructive, and the program carries Rare Pediatric Disease, Fast Track, Orphan Drug, and PRIME designations. Financially, Larimar ended 1Q26 with $200.4M in cash and marketable securities, guiding runway into 2Q27, while the rare-disease setting suggests a manageable launch footprint and meaningful long-term sales potential.

Larimar Therapeutics is constrained by its heavy dependence on nomlabofusp, a single clinical-stage asset, leaving the equity highly exposed to any safety setback, program termination, or failure to secure a differentiated label. Although the DCF framework assigns a 70% probability of approval and implies $1.19B of enterprise value and $1.33B of firm value, the company still faces meaningful regulatory, manufacturing, and intellectual property risks, including the possibility that the rolling BLA filing slips or FDA approval is delayed. The outlook is further pressured by likely future external financing and medium-term equity dilution, which could erode shareholder value if capital markets are less receptive and commercial traction after approval proves weak.